Reports Q3 revenue $47.725M, consensus $37.12M. “We made significant progress in the third quarter with record LIVMARLI revenues in both the United States and Internationally, the closing of the acquisition of CHENODAL and CHOLBAM and the positive top line results from the unblinding of the RESTORE trial of CHENODAL in CTX,” said Chris Peetz, president and chief executive officer at Mirum. “The company is well positioned to maintain this momentum with continued strong revenue growth and we look forward to multiple exciting upcoming clinical and regulatory catalysts.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MIRM:
- Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
- Cantor starts Mirum at Overweight on inhibitor portfolio expansion
- Mirum Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
- Mirum says FDA extends review of sNDA for LIVMARLI
- Mirum Pharmaceuticals resumed with an Outperform at Evercore ISI